- Home
- CRGX vs TCX Comparison
CRGX vs TCX Comparison
Compare CRGX & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- TCX
- Stock Information
- Founded
- CRGX 2021
- TCX 1992
- Country
- CRGX United States
- TCX Canada
- Employees
- CRGX N/A
- TCX N/A
- Industry
- CRGX
- TCX EDP Services
- Sector
- CRGX
- TCX Technology
- Exchange
- CRGX Nasdaq
- TCX Nasdaq
- Market Cap
- CRGX 190.0M
- TCX 215.1M
- IPO Year
- CRGX 2023
- TCX 1996
- Fundamental
- Price
- CRGX $4.25
- TCX $19.40
- Analyst Decision
- CRGX Hold
- TCX
- Analyst Count
- CRGX 7
- TCX 0
- Target Price
- CRGX $4.67
- TCX N/A
- AVG Volume (30 Days)
- CRGX 569.8K
- TCX 20.1K
- Earning Date
- CRGX 05-08-2025
- TCX 05-08-2025
- Dividend Yield
- CRGX N/A
- TCX N/A
- EPS Growth
- CRGX N/A
- TCX N/A
- EPS
- CRGX N/A
- TCX N/A
- Revenue
- CRGX N/A
- TCX $369,427,000.00
- Revenue This Year
- CRGX $58.18
- TCX N/A
- Revenue Next Year
- CRGX N/A
- TCX N/A
- P/E Ratio
- CRGX N/A
- TCX N/A
- Revenue Growth
- CRGX N/A
- TCX 6.66
- 52 Week Low
- CRGX $3.00
- TCX $13.27
- 52 Week High
- CRGX $25.45
- TCX $26.48
- Technical
- Relative Strength Index (RSI)
- CRGX 53.57
- TCX 63.05
- Support Level
- CRGX $3.78
- TCX $18.24
- Resistance Level
- CRGX $4.27
- TCX $19.95
- Average True Range (ATR)
- CRGX 0.18
- TCX 0.68
- MACD
- CRGX 0.03
- TCX 0.13
- Stochastic Oscillator
- CRGX 88.79
- TCX 81.17
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About TCX Tucows Inc.
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains.